Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Allison Berger"'
Autor:
Joseph B. Bolen, Erik Koenig, Michael Milhollen, Teresa A. Soucy, Usha Narayanan, Michael P. Thomas, James J. Garnsey, Louis M. Staudt, Mark Rolfe, Lawrence R. Dick, Tary Traore, Steven P. Langston, Julie Zhang, Jie Yu, Lenny Dang, Peter G. Smith, Allison Berger, Jennifer Adams-Duffy, Mark Manfredi
Publikováno v:
Blood. 116:1515-1523
MLN4924 is a potent and selective small molecule NEDD8-activating enzyme (NAE) inhibitor. In most cancer cells tested, inhibition of NAE leads to induction of DNA rereplication, resulting in DNA damage and cell death. However, in preclinical models o
Autor:
Bret Bannerman, Larry Dick, Mark Rolfe, Li Yu, Paul Hales, Jie Yu, Frank J. Bruzzese, Mark Manfredi, Edmund Lee, Michael Fitzgerald, Yueying Cao, Khristofer Garcia, Jane Liu, Joe Bolen, Erik Kupperman, Jonathan L. Blank, Paul E. Fleming, Yu Yang, Christopher Tsu, Allison Berger
Publikováno v:
Cancer Research. 70:1970-1980
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, severalgroups are pursuing the development
Autor:
Olga Tayber, Erik Kupperman, Zhi Li, Joseph B. Bolen, Ping Li, Kristen Bano, Jennifer Terkelsen, Allison Berger, Brian G Van Ness, Michael D. Pickard, Matthew D. Silva, Mary Carsillo, Paul Hales, Michael Fitzgerald, Siegfried Janz, Ozlem Subakan, Daniel P. Bradley, Mark Manfredi, Edmund Lee, Vishala T. Neppalli, Bret Bannerman, Jill Donelan, Raymond W. Liu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort